乳腺癌新分子分型中的P53蛋白表达及临床评估  

Expression of P53 protein in new molecular classification of breast cancer and clinical assessment

作　　者：刘祖宏[1] 倪仰鹏[1] 黄绮国[1] 许文兵[1] 陈宋钦[1] 

机构地区：[1]广东揭阳市人民医院病理科,揭阳522000

出　　处：《新医学》2013年第3期166-168,共3页Journal of New Medicine

摘　　要：目的:探讨P53蛋白在乳腺浸润性导管癌新分子分型中表达及其临床意义。方法:采用免疫组织化学方法 (二步法)检测92例乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、Ki-67和P53蛋白的表达,并进行新的分子分型及与P53蛋白相关性分析。结果:乳腺浸润性导管癌P53蛋白阳性表达率为53.3%,正常乳腺组织表达为阴性,两者比较差异有统计学意义(P<0.05)。HER-2过表达型和ER、PR、Ki-67三阴性型中P53蛋白阳性率明显高于Luminal A型、Luminal B1型、Luminal B2型,两者比较差异有统计学意义(P<0.05)。此外,乳腺淋巴结转移与P53蛋白呈正相关(r2=0.413,P<0.01)。结论:临床在使用ER、PR、HER-2、Ki-67四种指标对乳腺浸润性导管癌进行分型时同时检测P53蛋白,有助于评估肿瘤的生物学行为及预后。Objective： To investigate the expression of P53 protein in new molecular classification of breast cancer and clinical significance. Methods： Estrogen receptor （ER）, progestrone receptor （PR）, human epider- mal receptor 2 （HER-2） , Ki-67 and P53 expression were performed by irnmunohistochemical staining in 92 surgi- cal specimens of ductal breast carcinoma. The correlation between P53 expression and new molecular classification of breast cancer was analyzed. Results： P53 was negative in normal breast tissues while positive in 53.3% cases of breast cancer （P 〈 0. 05 ） ; The positive rate of P53 in HER-2 overexpression and triple-negative breast cancer was significantly higher than that those of Luminal A and B subtypes （P 〈 0.05 ）. Conclusion： Clinically, molecular classification of breast infiltrative ductal carcinoma via four items as ER, PR, HER-2, and ki-67 as well as detec- tion of P53 are helpful for the assessment of tumor biological behavior and prognosis.

关 键 词：乳腺癌 分子分型 免疫组织化学 P53蛋白 

分 类 号：R737.9[医药卫生—肿瘤]